Feb 22, 2024 4:05pm EST OPKO Health to Report Fourth Quarter 2023 Financial Results on February 27, 2024
Jan 09, 2024 4:05pm EST OPKO Health Announces Closing of Private Offering of $230 Million Convertible Senior Notes Due 2029 including Full Exercise of Initial Purchaser’s Option to Purchase Additional Notes
Jan 04, 2024 11:31pm EST OPKO Health Announces Pricing of Private Offering of $200 Million Convertible Senior Notes Due 2029
Nov 06, 2023 4:05pm EST OPKO Health Reports Third Quarter 2023 Business Highlights and Financial Results
Nov 02, 2023 10:00am EDT New Clinical Data on OPKO Health’s RAYALDEE® (ER Calcifediol) Presented at Kidney Week 2023
Oct 31, 2023 8:00am EDT OPKO Health to Report Third Quarter 2023 Financial Results on November 6, 2023
Oct 25, 2023 4:25pm EDT OPKO Health to Present New Clinical Data on Rayaldee (ER Calcifediol) at Kidney Week 2023
Sep 28, 2023 4:08pm EDT ModeX Therapeutics Secures BARDA Contract to Develop Novel Multispecific Antibodies Against Viral Infectious Disease Threats